within Pharmacolibrary.Drugs.V_Various.V09C_RenalSystem.V09CA03_Technetium99mtcMertiatid;

model Technetium99mtcMertiatid
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C(
    weight = 70,
    F = 1,
    Cl = 7.699999999999999e-06,
    adminDuration = 600,
    adminMass = 37 / 1000000,
    adminCount = 1,
    Vd = 0.00017999999999999998,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    Vdp = 8.999999999999999e-05,
    k12 = 2.3333333333333336e-06,
    k21 = 2.3333333333333336e-06);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Technetium99mtcMertiatide</td></tr><tr><td>ATC code:</td><td>V09CA03</td></tr><td>route:</td><td>intravenous</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>37</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>0.18</td><td>L</td></tr>
    <tr><td>clearance:</td><td>6.6</td><td>mL/min/kg</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Technetium (99mTc) mertiatide is a radiopharmaceutical agent used in nuclear medicine for renal imaging studies (renography) to assess renal perfusion, function, and to aid in the diagnosis of renal obstruction. It is administered exclusively by intravenous injection and is approved for clinical use in the evaluation of kidney function.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters estimated for adult subjects with normal renal function. Data based on typical diagnostic doses and standard practice for nuclear renal scans.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.V.V09CA03 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Technetium99mtcMertiatid;
